Investors and strategic partners do not need every experimental detail in the first conversation. They need to understand why the science matters, what has been shown, what remains to be proven and why the proposed development path is credible.
The challenge is not to make the science sound simple. The challenge is to make the strategic relevance of the science understandable. That means building a bridge from mechanism to clinical utility, and from clinical utility to commercial relevance.
Companies that can explain this bridge clearly are easier for investors and partners to assess through financing or partnering discussions.